Physician
Hematology
Dr. Barry C. Lembersky, MD
|
|
Give Review
Barry Lembersky works in the field of Hematology. Barry C. Lembersky has written publications. He has 56 publications published with PubMed. The lastest publication is: 'High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.' He is registered with Medicare.
Publications
- Prevention of bone loss with risedronate in breast Cancer survivors: a randomized, controlled clinical trial.
- Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic Cancer.
- Phase II Study of InDuction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic ...
- Breast Cancer: never too young for a functional assessment?
- Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer.
- A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer.
- Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer.
- Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic Cancer.
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast Cancer.
- Erratum: Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy.
- Metabolic effects of hormone deprivation therapy: weighing the evidence.
- Immunohistochemical surrogate markers of breast Cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
- Risedronate prevents bone loss in breast Cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
- Quality of life in operable colon Cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Proje...
- Diverticular disease in patients with colon Cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.
- Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III Carcinoma of the colon: results from National Surgica...
- Single-fraction radiosurgery for the treatment of spinal Breast metastases.
- Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast Cancer: results from national surgical adjuvant breast and bowel project t...
- Use of erythropoietin in Cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
- Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast Cancer: results from NSABP trial BP-58.
- Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal Cancer.
- Simultaneous Muir-Torre and Turcot's syndrome: A case report and review of the literature.
- Durability of responses to interferon alfa-2b in advanced hairy cell Leukemia.
- Skeletal complications in hairy cell Leukemia: diagnosis and therapy.
- Rapid response to 2'-deoxycoformycin in advanced hairy cell Leukemia after failure of interferons alpha and gamma.
- Fluorouracil, interferon-alpha, and colon Cancer: rational pursuit of synergism between antimetabolites and biologicals.
- Hairy cell Leukemia: clinical features and therapeutic advances.
- Implications of current therapeutic approaches in colorectal Cancer for other gastrointestinal malignancies.
- Metastases of unknown primary site.
- Cutaneous T-cell Lymphoma: value of CT in staging and determining prognosis.
- Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian Cancer after platinum: twenty-four-hour versus 7-day inf...
- Preoperative chemoradiotherapy for Carcinoma of the esophagus and gastroesophageal junction.
- Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast Cancer: National Surgical Adjuvant Br...
- UFT/leucovorin vs 5-FU/leucovorin in colon Cancer.
- Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal Cancer.
- Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast Cancer.
- Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast Cancer: results from NSABP B-28.
- NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consistin...
- Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate.
- High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast Cancer: hematopoieti...
- Has genetic testing for breast Cancer come of age?
- Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in ...
- Role of nutrition support during induction chemoradiation therapy in esophageal Cancer.
- Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for Carcinoma of the esophagus.
- High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast Cancer.
- Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast Cancer.
- Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced coloRectal carcinoma: an Eastern Cooperative Oncology Group study.
- Acute pulmonary failure in the conscious pony with Escherichia coli septicemia.
- Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast Cancer.
- A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate Cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
- High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast Cancer.
- Preoperative chemoradiotherapy and radical surgery for locally advanced distal Rectal adenocarcinoma: pathologic findings and clinical implications.
- Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience.
- The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast Cancer.
- Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast Cancer: a phase II trial of the NSABP Foundation Research Group.
Schools
Medical College of Pennsylvania
University Of Pittsburgh
University of Chicago
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Chicago -
University of Pittsburgh Medical Center
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1851362917 | |
| NPPES Provider LastName | LEMBERSKY | |
| NPPES Provider FirstName | BARRY | |
| NPPES Provider ZIPCode | 152321301 | |
| NPPES Provider State | PA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1151.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 47.0 | |
| Percent Opioid Claims | 4.08 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851362917 |
| Last Name Of The Provider | LEMBERSKY |
| First Name Of The Provider | BARRY |
| View All |
Similar Doctors
|
|
Dr. Mounzer E. Agha, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hongmei Liang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven A. Burton, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Swapna Goday, MD |
|
|
Dr. Alan N. Bress, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rohit R. Rao, MD |